RxSight, Inc. (RXST)
NASDAQ: RXST · IEX Real-Time Price · USD
46.77
+0.73 (1.59%)
At close: Jul 19, 2024, 4:00 PM
46.82
+0.05 (0.11%)
Pre-market: Jul 22, 2024, 7:10 AM EDT
RxSight Revenue
RxSight had revenue of $101.10M in the twelve months ending March 31, 2024, with 75.67% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $29.51M with 68.75% year-over-year growth. In the year 2023, RxSight had annual revenue of $89.08M with 81.77% growth.
Revenue (ttm)
$101.10M
Revenue Growth
+75.67%
P/S Ratio
18.03
Revenue / Employee
$270,324
Employees
374
Market Cap
1.82B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
Dec 31, 2019 | 2.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Harmony Biosciences Holdings | 617.51M |
NeoGenomics | 610.66M |
Veracyte | 375.47M |
Zai Lab | 291.07M |
Mirum Pharmaceuticals | 224.00M |
Ligand Pharmaceuticals | 118.31M |
Keros Therapeutics | 234.00K |
RXST News
- 6 weeks ago - RxSight, Inc. To Participate in the Truist Securities Medtech Conference - GlobeNewsWire
- 2 months ago - RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - RxSight, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - RxSight, Inc. Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024 - GlobeNewsWire
- 3 months ago - RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting - GlobeNewsWire
- 4 months ago - RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 months ago - RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference - GlobeNewsWire